fda 503b exclusions - Nexus Base

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by Anna Shvets on Pexels

fda 503b exclusions

Why FDA Excludes Semaglutide From Bulk?

2024 marks the year the FDA removed semaglutide from the 503B bulk list, a step taken to curb unauthorized compounding and protect patient safety. In short, the agency excluded the drug because it wants to keep unapproved compounding out of the mainstream pharmacy supply chain. Medical Disclaimer: This article is